F S&P 500
5,127.00 +44.75 (+0.88%) F Dow Jones
38,370.00 +82.00 (+0.21%) F Nasdaq
17,769.50 +202.00 (+1.15%) E-mini Russell 2000 Index Futur
1,991.20 -2.00 (-0.10%) Petróleo
84.03 +0.46 (+0.55%) Oro
2,350.20 +7.70 (+0.33%)
MediWound Ltd. (MDWD)
Fuera de horario:
MediWound Ltd.
42 Hayarkon Street
Yavne 8122745
Israel
972 7 797 14100
https://www.mediwound.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 100
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ofer Gonen B.Sc. | Chief Executive Officer | 649k | N/D | 1973 |
| Ms. Hani Luxenburg | Chief Financial Officer | 235k | N/D | 1973 |
| Dr. Lior Rosenberg M.D. | Co-Founder | 727k | N/D | 1946 |
| Dr. Shmulik Hess Ph.D. | COO & Chief Commercial Officer | N/D | N/D | 1973 |
| Mr. Yaron Meyer Adv. | Executive VP, General Counsel & Corporate Secretary | 240k | N/D | 1979 |
| Mr. Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | N/D | N/D | 1967 |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research & Development Officer | 393k | N/D | 1962 |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer | N/D | N/D | 1950 |
Descripción
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Gestión corporativa
La calificación ISS Governance QuickScore de MediWound Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
